Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Jo Ann W. Byl"'
Autor:
Soziema E. Dauda, Jessica A. Collins, Jo Ann W. Byl, Yanran Lu, Jack C. Yalowich, Mark J. Mitton-Fry, Neil Osheroff
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 15, p 12107 (2023)
Novel bacterial topoisomerase inhibitors (NBTIs) are an emerging class of antibacterials that target gyrase and topoisomerase IV. A hallmark of NBTIs is their ability to induce gyrase/topoisomerase IV-mediated single-stranded DNA breaks and suppress
Externí odkaz:
https://doaj.org/article/57dad8cf2974442080082568e056354a
Autor:
Eric D. Huseman, Jo Ann W. Byl, Scott M. Chapp, Nathan D. Schley, Neil Osheroff, Steven D. Townsend
Publikováno v:
ACS Central Science, Vol 7, Iss 8, Pp 1327-1337 (2021)
Externí odkaz:
https://doaj.org/article/94bd430164004b28a3afec0b42954363
Publikováno v:
Cell Reports, Vol 29, Iss 2, Pp 422-436.e5 (2019)
Summary: Termination of DNA replication occurs when two replication forks converge upon the same stretch of DNA. Resolution of topological stress by topoisomerases is crucial for fork convergence in bacteria and viruses, but it is unclear whether sim
Externí odkaz:
https://doaj.org/article/67627de22a2c4fa79af325886887e2a1
Publikováno v:
ACS Infectious Diseases. 9:706-715
Autor:
Preshendren Govender, Rudolf Müller, Kawaljit Singh, Virsinha Reddy, Charles J. Eyermann, Stephen Fienberg, Sandeep R. Ghorpade, Lizbé Koekemoer, Alissa Myrick, Dirk Schnappinger, Curtis Engelhart, Jaclynn Meshanni, Jo Ann W. Byl, Neil Osheroff, Vinayak Singh, Kelly Chibale, Gregory S. Basarab
Publikováno v:
J Med Chem
This is the accepted manuscript version of the work published in its final form as Govender, P., Müller, R., Singh, K., Reddy, V., Eyermann, C. J., Fienberg, S., Ghorpade, S. R., Koekemoer, L., Myrick, A., Schnappinger, D., Engelhart, C., Meshanni,
Autor:
Jeffrey Y Jian, Kevin D McCarty, Jo Ann W Byl, F Peter Guengerich, Keir C Neuman, Neil Osheroff
Publikováno v:
Nucleic Acids Res
To perform double-stranded DNA passage, type II topoisomerases generate a covalent enzyme-cleaved DNA complex (i.e. cleavage complex). Although this complex is a requisite enzyme intermediate, it is also intrinsically dangerous to genomic stability.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a00dba8a24a38260445f90e51df0603
https://europepmc.org/articles/PMC10164583/
https://europepmc.org/articles/PMC10164583/
Publikováno v:
The FASEB Journal. 35
Autor:
Katherine L Furniss, Hung-Ji Tsai, Jo Ann W Byl, Andrew B Lane, Amit C Vas, Wei-Shan Hsu, Neil Osheroff, Duncan J Clarke
Publikováno v:
PLoS Genetics, Vol 9, Iss 10, p e1003832 (2013)
By necessity, the ancient activity of type II topoisomerases co-evolved with the double-helical structure of DNA, at least in organisms with circular genomes. In humans, the strand passage reaction of DNA topoisomerase II (Topo II) is the target of s
Externí odkaz:
https://doaj.org/article/925baffde6b44627b6f84bc643f95894
Autor:
Marco De Vivo, Jose M. Arencibia, Vito Genna, Maria Summa, Sine Mandrup Bertozzi, Elirosa Minniti, Andrea Armirotti, Sebastian Franco-Ulloa, Jo Ann W. Byl, Claudia Sissi, Rosalia Bertorelli, Neil Osheroff, Marco Borgogno, Anna Minarini, Jose Antonio Ortega
Publikováno v:
J Med Chem
We disclose a novel class of 6-amino-tetrahydroquinazoline derivatives that inhibit human topoisomerase II (topoII), a validated target of anticancer drugs. In contrast to topoII-targeted drugs currently in clinical use, these compounds do not act as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71bc28cb9ef7c7a4bbe71fd55bf4856c
http://hdl.handle.net/11577/3367154
http://hdl.handle.net/11577/3367154
Autor:
Rachael E Hawtin, David E Stockett, Jo Ann W Byl, Robert S McDowell, Tan Nguyen, Michelle R Arkin, Andrew Conroy, Wenjin Yang, Neil Osheroff, Judith A Fox
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10186 (2010)
Topoisomerase II is critical for DNA replication, transcription and chromosome segregation and is a well validated target of anti-neoplastic drugs including the anthracyclines and epipodophyllotoxins. However, these drugs are limited by common tumor
Externí odkaz:
https://doaj.org/article/13467f009c0841b5998d831560bc564d